MyPeptideMatchMazdutide (IBI362) is a weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, currently in Phase 3 trials in China. Phase 3 GLORY-1 trial data showed 14.5% body weight reduction over 36 weeks.
GLP-1/Glucagon Dual Agonist
Mazdutide (IBI362) is a weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, currently in Phase 3 trials in China. Phase 3 GLORY-1 trial data showed 14.5% body weight reduction over 36 weeks.
Research Use Only — not intended for human consumption
Research peptides are sold for laboratory use only and are not intended for human consumption.
Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.
Week-by-week dosing protocolNo clinics in our directory yet. Browse all clinics.
Find a Peptide Clinic Near YouMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.